Kiran Mazumdar Shaw

Immuneel Therapeutics, backed by entrepreneur Kiran Mazumdar-Shaw, offers therapy for CAR T-cell therapy for adult B-cell non-hodgkin lymphoma (B-NHL)

Biocon Group Chairperson Kiran Mazumdar-Shaw was conferred the prestigious Jamsetji Tata Award by the Indian Society for Quality (ISQ) on Saturday for pioneering the biosciences movement in India. "This award holds a very special meaning to me as it is named after one of India's greatest visionaries - a man whose legacy of excellence, innovation, and nation-building continues to inspire us all. Jamsetji Tata's commitment to quality and his belief in the transformative power of industry to serve society resonate deeply with my own journey," said Mazumdar-Shaw. The Jamsetji Tata Award, instituted in 2004 by ISQ recognises business leaders who have made significant contributions to Indian society. The Award was announced at the ISQ Annual Conference 2024, held in Bengaluru. Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman and Managing Director, TQM International. "This Lifetime achievement award is being presented to Kiran Mazumdar-Shaw for being

Biocon Group Chairperson Kiran Mazumdar-Shaw was conferred the prestigious Jamsetji Tata Award by the Indian Society for Quality (ISQ) on Saturday for pioneering the biosciences movement in India. "This award holds a very special meaning to me as it is named after one of India's greatest visionaries - a man whose legacy of excellence, innovation, and nation-building continues to inspire us all. Jamsetji Tata's commitment to quality and his belief in the transformative power of industry to serve society resonate deeply with my own journey," said Mazumdar-Shaw. The Jamsetji Tata Award, instituted in 2004 by ISQ recognises business leaders who have made significant contributions to Indian society. The Award was announced at the ISQ Annual Conference 2024, held in Bengaluru. Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman and Managing Director, TQM International. "This Lifetime achievement award is being presented to Kiran Mazumdar-Shaw for being

Says today, we are at an inflection point when it comes to technology. Up until now, we used to scratch at the surface because we couldn't really understand the mysteries of biology

Biocon Chairperson Kiran Mazumdar-Shaw on Thursday called for more investment in research and development to drive innovation and foster culture of intellectual property. She highlighted how the country, already the world's largest exporter of generics and a major player in vaccine production, can achieve greater value by nurturing innovation. Mazumdar-Shaw called for a shift in focus toward value creation through innovation. "India ranks 14th in terms of value in the global pharma landscape. We need to invest in R&D and foster a culture of intellectual property to capture greater value," she said. Addressing a session during the Global Bio-India 2024 event, she positioned the country as a future global leader in biosciences and innovation. Mazumdar-Shaw emphasized India's unique advantages in becoming a global bio-innovation hub, citing the nation's rich scientific talent, robust technological capabilities, and entrepreneurial drive. "Biology is not only the most exciting and ...

Kiran outlines how being vertically integrated puts Biocon in a strong position

Bengaluru-based company announces 'strategic partnership' with Handok

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

Research-based incentives to develop innovative drugs can help the domestic pharmaceutical sector to be worth USD 200 billion by 2030, Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Wednesday. Terming the pharmaceutical sector as a great contributor in the country's economic growth, she noted that the industry has even greater potential to grow in the years to come. "India's pharma industry size is estimated at about USD 65 billion today. And by 2030, it is expected to increase to USD 165 billion. Now, I believe it has a potential to even be greater and touch USD 200 billion by 2030," Mazumdar-Shaw told PTI. But such a level of growth cannot just be driven by generics and biosimilars, it has to involve drug innovation, she noted. "We have time to develop new drugs which could be blockbusters and I think what is required are research incentives to drive this kind of growth," Mazumdar-Shaw stated. The government has already come out with various research-linked incentive .

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

On a sequential basis, the company exhibited a 1.15 per cent increase in revenue along with PAT, which rose 23.8 per cent

The earlier investment by SILS in BBL was at a valuation of $4.9 billion, and the fresh $150-million investment pushes it up at $6 billion

D Sundaram appointed lead independent director of IT services company

It's a high growth phase for us in Biocon Biologics: We crossed the Rs 1,500-crore mark in revenue for the first time this quarter. We will exit this year (FY23) at Rs 2,000-crore level

Biocon Chief Kiran Majumdar-Shaw, who lost her husband, stated that she is devastated. Sharing her thoughts on social media, she maintained that she will always be guided by her husband John Shaw

Biocon founder Kiran Mazumdar-Shaw said she was devastated to lose her husband and will miss him profoundly. John Shaw, who had served the Bengaluru-headquartered biopharmaceutical company as the Vice-Chairman and Non-Executive Director for over 22 years, passed away at a private hospital here on Monday. "I am devastated to lose my husband, my mentor and soul mate. I will always be spiritually guided by John as I pursue my purpose. Rest in Peace my darling John. Thank you for making my life so very special. I will miss you profoundly," Mazumdar-Shah said. John Shaw, a Scotsman and Indophile, headed a leading textiles MNC Madura Coats as Chairman and Managing Director before joining Biocon in 1999. "He has contributed majorly to the transformation of Biocon from a small enzymes company to a globally recognised biopharmaceutical company and has played an important role in ensuring the highest levels of corporate governance in the company, as well as, in the financial and strategic .

Biocon executive chairperson Kiran Mazumdar Shaw's husband John Shaw passed away on Monday morning in a private hospital, family sources said. He was 73. Shaw was admitted to the hospital where he was undergoing treatment, they said. The exact reason behind the death was not known. Shaw was the former vice chairman of the Bengaluru-headquartered Biocon Limited. He was an MA (Economics Honours) in History and Political Economy from the University of Glasgow in United Kingdom. He was also the former chairman of Madura Coats Limited and former finance and managing director of Coats Viyella Group.

Biotechnology industry veteran Kiran Mazumdar-Shaw has suggested penalising city civic body Bruhat Bengaluru Mahanagara Palike (BBMP) and Bangalore Development Authority (BDA) for giving permissions leading to encroachments of storm water drains (SWDs) that resulted in the recent floods. The Executive Chairperson of Bengaluru-headquartered biopharmaceuticals company Biocon said the anti-encroachment drive launched by the BMMP this week to clear illegal structures sitting on SWDs, is a long overdue measure to address water logging which caused unprecedented havoc in parts of Bengaluru two weeks ago. "The question that begs to be answered is whether there will be a parallel investigation into how the BBMP and BDA gave permissions in the first place", she told PTI. "Moreover, we need to go beyond knee jerk quick fixes and find holistic long term solutions. For example, razing buildings will impact helpless and innocent homeowners. Why not penalise developers and BDA/BBMP and use that